Heart failure with mildly reduced ejection fraction (HFmrEF) affects up to 25% of patients with heart failure, yet many clinicians remain uncertain about how best to diagnose and treat it. In this episode, HFSA Scientific Statement co-authors Jane E. Wilcox, MD, and Barry A. Borlaug, MD, discuss the evidence, clinical implications, and key takeaways from the newly published HFSA Scientific Statement.

Read the Scientific Statement: HFSA Scientific Statement: Heart Failure with Mildly Reduced Ejection Fraction

The May (2026) issue of the Journal of Cardiac Failure shines a spotlight on infiltrative and inflammatory cardiomyopathies, including amyloidosis, sarcoidosis, and myocarditis, and the rapidly evolving science shaping their future.

On this episode of the Heart Failure Beat, guest editors Drs. Nisha A. Gilotra, Mathew Maurer and Emer Joyce discuss the diagnostic challenges these patients face, the rise of non-biopsy diagnosis, emerging targeted therapies, AI-driven diagnostics, multidisciplinary care models, and why earlier recognition is transforming outcomes.

The conversation also explores how the field is evolving for trainees, researchers, and patients alike, and why this special focus issue may represent a launchpad for innovation across heart failure care.

Are mineralocorticoid receptor antagonists (MRAs) ready for prime time in HFpEF and HFmrEF?

In this special debate-format episode of the Heart Failure Beat, two leading heart failure pharmacists, Stormi Gale, PharmD, BCCP, FHFSA and Robert L Page II, PharmD, MSPH, FHFSA, go head-to-head on steroidal vs non-steroidal MRAs.

From RALES and TOPCAT to FINEARTS-HF, they unpack the evidence, guideline implications, cost-effectiveness, CKM considerations, and real-world barriers to access. Is finerenone the “new pillar” in HFpEF? Or does spironolactone remain the practical, evidence-based choice? The conversation also explores phenotyping challenges in HF trials and whether combining SGLT2 inhibitors with MRAs can attenuate hyperkalemia risk.

If you care about precision medicine, cardiorenal overlap, or optimizing GDMT in complex patients, this debate is for you.